2023
Mutation-specific costs of advanced non-small cell lung cancer treatment.
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerMean medication costsActionable gene alterationsMedication costsFirst-year costsReference groupAdvanced non-small cell lung cancer (NSCLC) treatmentNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentGene alterationsBiomarker resultsFlatiron Health databasePD-L1 resultsTherapy prolongs survivalRetrospective cohort studyCell lung cancerBiomarker test resultsLung cancer treatmentCost-effectiveness analysisCohort studyNovel immunotherapiesOverall cohortProlong survivalTreatment options
2012
Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical Trial
DeWitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Lin L, Schulman KA, Reed SD. Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical Trial. Value In Health 2012, 15: 277-283. PMID: 22433759, DOI: 10.1016/j.jval.2011.11.027.Peer-Reviewed Original ResearchConceptsLung functionMild impairmentCystic fibrosisClinical trialsAeruginosa colonizationHealth Utilities Index Mark 2/3Study case report formsPrimary end pointNationwide Inpatient SampleDirect medical costsMulticenter clinical trialP. aeruginosa colonizationPseudomonas aeruginosa colonizationMean annual costCase report formsLong-term useUtility estimatesEmergency visitsHospital admissionDornase alfaMedication costsRandomized trialsMean ageFemale sexInpatient Sample